Yüklüyor......
非小细胞肺癌T790M基因突变研究进展
Patients with advanced non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) activating mutations benefit from EGFR-tyrosine kinase inhibitor (TKI) treatment, however, most of TKI-treated patients eventually suffer drug resistant after 10-month treatments. Previous stud...
Kaydedildi:
| Yayımlandı: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
中国肺癌杂志编辑部
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000573/ https://ncbi.nlm.nih.gov/pubmed/23769347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.08 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|